미세생리 시스템 시장 : 세계 예측(2026-2032년)

The Microphysiological System Market is projected to grow by USD 498.01 million at a CAGR of 17.18% by 2032.

Microphysiological Systems: Executive Overview

Microphysiological systems (MPS) are engineered in vitro platforms that reproduce selected structural, mechanical, biochemical, and functional features of human tissues or organs. Often described as organ-on-chip or tissue-on-chip systems, they combine human cells, biomaterials, microfluidics, sensors, and computational analysis to support research, safety assessment, and translational development. Their value lies in generating human-relevant evidence while reducing dependence on conventional two-dimensional cultures and selected animal studies. Adoption remains shaped by biological reproducibility, protocol standardization, validation requirements, regulatory acceptance, workflow integration, and the availability of specialized expertise.

From Static Cell Models to Human-Relevant Experimental Platforms

The field is shifting from isolated proof-of-concept devices toward more reproducible platforms designed for repeatable use across research and development workflows. Important changes include greater use of primary and stem-cell-derived human cells, multicellular co-culture, perfused tissue models, integrated sensing, and linked organ systems. Researchers are also placing greater emphasis on standardized operating procedures, reference materials, interlaboratory comparison, and transparent reporting of model limitations. These developments are helping position MPS as complementary tools for target validation, toxicity assessment, disease modeling, pharmacology, and personalized research rather than as standalone replacements for every existing method.

Artificial Intelligence Strengthens Model Design, Interpretation, and Quality Control

Artificial intelligence is influencing MPS through image analysis, time-series interpretation, experimental optimization, and prediction of tissue responses. Machine-learning methods can help quantify morphology, barrier integrity, contractility, electrophysiology, metabolic activity, and other phenotypic signals that are difficult to evaluate consistently by manual review. Digital-twin concepts and mechanistic models may further support integration of data from multiple tissues and experimental conditions. However, useful deployment depends on well-annotated datasets, consistent assay procedures, explainable outputs, protection against batch effects, and independent validation. AI can accelerate analysis and improve reproducibility, but it does not remove the need for biological controls, domain expertise, or regulatory scrutiny.

Regional Insights: Regulation, Infrastructure, and Translation Shape Adoption

North America combines strong biomedical research capacity, biotechnology activity, and interest in alternative testing approaches, while implementation is influenced by validation and regulatory expectations. Europe benefits from coordinated research networks, advanced life-science infrastructure, and policy attention to non-animal methods, with cross-border standardization remaining important. Asia-Pacific shows diverse development across Australia, China, India, Japan, and South Korea, supported by advanced manufacturing, pharmaceutical research, and public-sector science programs. Latin America, including Brazil and Mexico, is developing capabilities through academic, pharmaceutical, and translational partnerships, although access to specialized equipment and funding can vary. The Middle East is building research and innovation capacity in selected hubs, while Africa presents opportunities for locally relevant disease models and collaborative development alongside constraints related to infrastructure, training, and procurement.

Group Insights: Collaboration Networks Accelerate Standardization

ASEAN economies can benefit from shared protocols, regional training, and collaborative biobanking that reduce duplication across developing MPS programs. BRICS members offer substantial scientific and clinical diversity, making joint validation studies and locally relevant disease models particularly valuable. The European Union provides a framework for coordinated research, harmonized documentation, and regulatory dialogue across member states. G7 countries contribute mature biomedical ecosystems, advanced instrumentation, and policy engagement, but continued alignment is needed to make evidence portable between jurisdictions. GCC members can support adoption through centralized research facilities, translational investment, and partnerships with international institutions. NATO countries, viewed as a research and technology network rather than a single regulatory market, may gain from interoperable standards and shared expertise in biosafety, resilience, and advanced biomedical engineering.

Country Insights: Diverse Capabilities Create Complementary Roles

The United States and Canada have established strengths in biomedical engineering, drug development, and translational research. The United Kingdom, Germany, France, Italy, and Spain contribute through university-led innovation, pharmaceutical research, and European collaborative programs, with harmonized validation remaining a priority. Japan and South Korea combine advanced electronics, materials science, and life-science capabilities, supporting sensor integration and automated platforms. China is expanding research and manufacturing capacity across microfluidics, cell biology, and pharmaceutical applications. India is developing MPS expertise through academic, biotechnology, and pharmaceutical collaborations, while Australia contributes strong biomedical research and translational science. Brazil and Mexico are important Latin American contributors, with opportunities to connect academic capability to industrial validation. Russia maintains relevant scientific expertise, although international collaboration, access to equipment, and regulatory connectivity can affect deployment.

Industry Priorities: Build Validated, Interoperable, and Decision-Ready Platforms

Industry leaders should prioritize clearly defined use cases and select model complexity according to the decision being supported. Establishing standardized protocols, acceptance criteria, quality controls, and documented performance characteristics is essential before scaling deployment. Organizations should create multidisciplinary teams spanning biology, engineering, data science, toxicology, pharmacology, and regulatory affairs. Partnerships with academic centers, contract research organizations, technology developers, and public agencies can improve validation and reduce implementation risk. Leaders should also invest in interoperable data systems, AI governance, staff training, and evidence packages that connect MPS outputs with established clinical, preclinical, and regulatory endpoints. A staged approach-pilot, reproduce, benchmark, then integrate-offers a practical path to responsible adoption.

Research Methodology: Evidence-Based Synthesis of the MPS Landscape

This executive summary is based on a structured review of the microphysiological systems field, organized around technology development, applications, enabling infrastructure, regulation, artificial intelligence, and geographic adoption conditions. Evidence should be assessed using peer-reviewed studies, regulatory and standards publications, government or intergovernmental materials, validated technical documentation, and relevant clinical or translational research records. Findings are interpreted comparatively across the specified regions, country groups, and countries, with attention to differences in scientific capacity, funding, manufacturing, policy, and implementation readiness. Because platform performance can vary by tissue type, cell source, device architecture, and assay endpoint, conclusions should distinguish demonstrated capabilities from emerging possibilities and avoid treating all MPS formats as interchangeable.

Conclusion: Translation Depends on Trustworthy Evidence and Practical Integration

Microphysiological systems are becoming important tools for producing more human-relevant biological evidence across research, safety, and therapeutic development. Their long-term contribution will depend less on novelty alone than on reproducibility, standardization, transparent validation, and compatibility with existing decision processes. Regional and country-level strengths are complementary, creating opportunities for shared protocols, cross-border benchmarking, and responsible data integration. Artificial intelligence can extend the usefulness of MPS, provided that data quality, interpretability, and biological validation remain central. Organizations that focus on clearly defined applications and decision-ready evidence will be best positioned to convert technological progress into reliable scientific and operational value.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. New Revenue Opportunities
• 3.4. Next-Generation Business Models
• 3.5. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Microphysiological System Market, by Technology

• 7.1. Introduction
• 7.2. Organ On Chip
• 7.3. Organoids
• 7.4. Microfluidics
• 7.5. 3D Bioprinting
• 7.6. Spheroids

8. Microphysiological System Market, by System Type

• 8.1. Introduction
• 8.2. Single-organ models
• 8.3. Multi-organ (body-on-a-chip) systems

9. Microphysiological System Market, by Research Model

• 9.1. Introduction
• 9.2. Human cell-based MPS
• 9.3. Animal cell-based MPS
• 9.4. Stem cell (iPSC) based models
• 9.5. Hybrid/organotypic models

10. Microphysiological System Market, by Offering

• 10.1. Introduction
• 10.2. System/Solution
• 10.3. Services
• 10.4. Consumables

11. Microphysiological System Market, by Application

• 11.1. Introduction
• 11.2. Drug discovery & screening
• 11.3. Disease modeling
• 11.4. Toxicology & safety assessment
• 11.5. Personalized medicine
• 11.6. Regulatory testing
• 11.7. Bioavailability & efficacy studies

12. Microphysiological System Market, by End User

• 12.1. Introduction
• 12.2. Pharmaceutical & biotechnology companies
• 12.3. Academic & research institutes
• 12.4. Contract Research Organizations (CROs)
• 12.5. Government & regulatory agencies
• 12.6. Hospitals & clinical research centers

13. Microphysiological System Market, by Deployment Mode

• 13.1. Introduction
• 13.2. In-house lab installations
• 13.3. Outsourced MPS services

14. Microphysiological System Market, by Region

• 14.1. Introduction
• 14.2. Asia-Pacific
• 14.3. Europe
• 14.4. North America
• 14.5. Latin America
• 14.6. Africa
• 14.7. Middle East

15. Microphysiological System Market, by Group

• 15.1. Introduction
• 15.2. NATO
• 15.3. G7
• 15.4. European Union
• 15.5. BRICS
• 15.6. ASEAN
• 15.7. GCC

16. Microphysiological System Market, by Country

• 16.1. Introduction
• 16.2. United States
• 16.3. China
• 16.4. Germany
• 16.5. Japan
• 16.6. India
• 16.7. United Kingdom
• 16.8. France
• 16.9. Canada
• 16.10. Italy
• 16.11. Australia
• 16.12. Brazil
• 16.13. South Korea
• 16.14. Mexico
• 16.15. Russia
• 16.16. Spain

17. Competitive Landscape

• 17.1. Market Share Analysis, 2025
• 17.2. Market Concentration Analysis, 2025
  • 17.2.1. Concentration Ratio (CR)
  • 17.2.2. Herfindahl Hirschman Index (HHI)
• 17.3. Recent Developments & Impact Analysis, 2025
• 17.4. Product Portfolio Analysis, 2025
• 17.5. Benchmarking Analysis, 2025

18. Company Profiles

• 18.1. Emulate, Inc.
• 18.2. CN Bio Innovations Ltd.
• 18.3. InSphero AG
• 18.4. TissUse GmbH
• 18.5. MIMETAS BV
• 18.6. Hesperos, Inc.
• 18.7. SynVivo, Inc.
• 18.8. Cherry Biotech SAS
• 18.9. BioIVT LLC
• 18.10. Kirkstall Ltd.
• 18.11. AIM Biotech Pte. Ltd.
• 18.12. Altis Biosystems, Inc.
• 18.13. AlveoliX AG
• 18.14. Ananda Devices
• 18.15. Beijing Daxiang Biotech Co., Ltd
• 18.16. BI/OND Solutions B.V.
• 18.17. BiomimX S.r.l.
• 18.18. FUJIFILM Cellular Dynamics
• 18.19. ImmuONE
• 18.20. Netri, Inc.
• 18.21. Obatala Sciences, Inc.
• 18.22. Quris Technologies LTD
• 18.23. React4life S.p.A.
• 18.24. Valo Health, Inc.

19. Key Experts